Riboflavin, as a measure of compliance (available on 76 individuals) was measured with fluorometric assay based on standard curves of weighed-in riboflavin (Anton, 1996). Compliance was defined as either a day-6 urine riboflavin over 1500 ug/ml or a doubling from pre-study baseline to day-6. There were 88% (Ntx/asn40), 83% (Ntx/asp40), 75% (placebo/asn40), and 90% (placebo/asp40) compliant individuals that did not differ significantly between medication groups (X2 =0.110, p=0.74) or genotype (X2 = 0.531, p=0.47).
